Resverlogix Corp.
OTC: RVXCF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Donald J. McCaffrey
- Employees
- 19
- Headquarters
- Calgary, Canada
- IPO year
- 2009
- Market cap
- $22.2M
- Website
- https://www.resverlogix.com
Loading RVXCF…
Loading profile data…Frequently asked questions about RVXCF
What does Resverlogix Corp. (RVXCF) do?
Resverlogix Corp. is an advanced-stage biotechnology company that focuses on developing therapies for medical conditions with significant unmet needs. The company's primary asset is apabetalone (RVX-208), a specialized small molecule bromodomain and extra-terminal inhibitor, which is currently undergoing Phase III clinical trials. This investiga...
Where does RVXCF trade?
Resverlogix Corp. (RVXCF) trades on the Other OTC.
What sector is RVXCF in?
Resverlogix Corp. (RVXCF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Resverlogix Corp.?
Donald J. McCaffrey is the chief executive officer of Resverlogix Corp. (RVXCF).
Where is Resverlogix Corp. headquartered?
Resverlogix Corp. is headquartered in Canada.
Does RVXCF pay a dividend?
Resverlogix Corp. (RVXCF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RVXCF go public?
Resverlogix Corp. (RVXCF) completed its initial public offering in 2009.